The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to ... UCCD study in patients with moderate-to-severe ulcerative colitis (UC) and Crohn's disease suggest a "best ...

Sanofi has acquired rights to co-develop and co-market Teva’s TEV-48574, currently in phase 2b testing for both ulcerative colitis and Crohn’s disease, with results expected next year.

TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV’574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' Stelara biosimilar over an unauthorized sublicense deal ...

AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, and ...

According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...

In patients with ulcerative colitis, vedolizumab outperformed infliximab as a second-line therapy following failure of ...

Teva's business is encountering headwinds, including declining U.S. generics revenue. Read what this biotech plans to do in ...